Pharmacological Agents and Potential New Therapies in Pulmonary Arterial Hypertension

Overview

Journal Curr Vasc Pharmacol

Publisher Bentham Science Publishers

Date 2023 Dec 20

PMID 38115617

Authors

Renata Trabach Santos

Maria Eduarda de Sa Freire Onofre

Dayene de Assis Fernandes Caldeira

Adriane Bello Klein

Patricia Rieken Macedo Rocco

Fernanda Ferreira Cruz

Pedro Leme Silva

Affiliations

Soon will be listed here.

Abstract

Pulmonary arterial hypertension (PAH) is a progressive disease characterized by an imbalance between vasoactive mediators, which causes vascular remodeling, increased pulmonary vascular resistance, and right ventricular overload, ultimately leading to heart failure and death. A metabolic theory has been suggested to explain the pathophysiology of PAH whereby abnormalities in mitochondrial biogenesis can trigger a hyperproliferative and apoptosis-resistant phenotype in cardiopulmonary and malignant cells, leading to mitochondrial dysfunction, which in turn causes the Warburg effect. This can culminate in the mitophagy of pulmonary vessels and cardiomyocytes. The present narrative review focuses on the pathophysiology of PAH, the pharmacological agents currently available for its treatment, and promising and challenging areas of therapeutic investigation.

References

Vazquez Z, Klinger J . Guidelines for the Treatment of Pulmonary Arterial Hypertension. Lung. 2020; 198(4):581-596. DOI: 10.1007/s00408-020-00375-w. View

Galie N, McLaughlin V, Rubin L, Simonneau G . An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J. 2018; 53(1). PMC: 6351332. DOI: 10.1183/13993003.02148-2018. View

Humbert M, Kovacs G, Hoeper M, Badagliacca R, Berger R, Brida M . 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2022; 61(1). DOI: 10.1183/13993003.00879-2022. View

Hoeper M, Bogaard H, Condliffe R, Frantz R, Khanna D, Kurzyna M . Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013; 62(25 Suppl):D42-50. DOI: 10.1016/j.jacc.2013.10.032. View

Montani D, Gunther S, Dorfmuller P, Perros F, Girerd B, Garcia G . Pulmonary arterial hypertension. Orphanet J Rare Dis. 2013; 8:97. PMC: 3750932. DOI: 10.1186/1750-1172-8-97. View

Beshay S, Sahay S, Humbert M . Evaluation and management of pulmonary arterial hypertension. Respir Med. 2020; 171:106099. DOI: 10.1016/j.rmed.2020.106099. View

Poch D, Mandel J . Pulmonary Hypertension. Ann Intern Med. 2021; 174(4):ITC49-ITC64. DOI: 10.7326/AITC202104200. View

Kim D, George M . Pulmonary Hypertension. Med Clin North Am. 2019; 103(3):413-423. DOI: 10.1016/j.mcna.2018.12.002. View

Maron B, Abman S, Elliott C, Frantz R, Hopper R, Horn E . Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances. Am J Respir Crit Care Med. 2021; 203(12):1472-1487. PMC: 8483220. DOI: 10.1164/rccm.202012-4317SO. View

10.

Valverde A, Soares J, Viana K, Gomes B, Soares C, Souza R . Pulmonary arterial hypertension in Latin America: epidemiological data from local studies. BMC Pulm Med. 2018; 18(1):106. PMC: 6019295. DOI: 10.1186/s12890-018-0667-8. View

11.

Hoeper M, Humbert M, Souza R, Idrees M, Kawut S, Sliwa-Hahnle K . A global view of pulmonary hypertension. Lancet Respir Med. 2016; 4(4):306-22. DOI: 10.1016/S2213-2600(15)00543-3. View

12.

Henrohn D, Bjorkstrand K, Lundberg J, Granstam S, Baron T, Ingimarsdottir I . Effects of Oral Supplementation With Nitrate-Rich Beetroot Juice in Patients With Pulmonary Arterial Hypertension-Results From BEET-PAH, an Exploratory Randomized, Double-Blind, Placebo-Controlled, Crossover Study. J Card Fail. 2018; 24(10):640-653. DOI: 10.1016/j.cardfail.2018.09.010. View

13.

Leonidas Alves Jr J, Gavilanes F, Jardim C, Fernandes C, Morinaga L, Dias B . Pulmonary arterial hypertension in the southern hemisphere: results from a registry of incident Brazilian cases. Chest. 2014; 147(2):495-501. DOI: 10.1378/chest.14-1036. View

14.

Luna-Lopez R, Ruiz Martin A, Escribano Subias P . Pulmonary arterial hypertension. Med Clin (Barc). 2022; 158(12):622-629. DOI: 10.1016/j.medcli.2022.01.003. View

15.

Boucly A, Weatherald J, Savale L, Jais X, Cottin V, Prevot G . Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017; 50(2). DOI: 10.1183/13993003.00889-2017. View

16.

Lan N, Massam B, Kulkarni S, Lang C . Pulmonary Arterial Hypertension: Pathophysiology and Treatment. Diseases. 2018; 6(2). PMC: 6023499. DOI: 10.3390/diseases6020038. View

17.

Ding X, Liang H, Yuan B, Li L, Wang T, Kan Q . Efficacy of stem cell therapy for pulmonary arterial hypertension: a systematic review and meta-analysis of preclinical studies. Stem Cell Res Ther. 2019; 10(1):55. PMC: 6374914. DOI: 10.1186/s13287-019-1162-8. View

18.

Bourgeois A, Omura J, Habbout K, Bonnet S, Boucherat O . Pulmonary arterial hypertension: New pathophysiological insights and emerging therapeutic targets. Int J Biochem Cell Biol. 2018; 104:9-13. DOI: 10.1016/j.biocel.2018.08.015. View

19.

Voelkel N, Quaife R, Leinwand L, Barst R, McGoon M, Meldrum D . Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation. 2006; 114(17):1883-91. DOI: 10.1161/CIRCULATIONAHA.106.632208. View

20.

Schermuly R, Ghofrani H, Wilkins M, Grimminger F . Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol. 2011; 8(8):443-55. PMC: 7097518. DOI: 10.1038/nrcardio.2011.87. View